E xpands GEN-1 P rogram C ollaboration to Add   C linical and C ommercial B atches of I nvestigational V accine LAWRENCEVILLE, N.J. and HAINAN, China , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ) , a clinical-stage company focused on DNA-based immunotherapy and

Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecular Adjuvant LAWRENCEVILLE, N.J. , Sept.

Strong Balance Sheet Supports Focus i n Immuno-Oncology and on   Next-Generation Vaccine Initiative Conference Call Begins Today   at 11:00 a.m.   Eastern Time LAWRENCEVILLE, N.J. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company

LAWRENCEVILLE, N.J. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.

Data show d ose - dependent suppression of immun e- suppressive agents GEN-1 stimulate s the immune system through the production of CD4 and CD8 cells C hemotherapy R esponse Score tripled in the two highest doses of GEN-1 and is double that of chemotherapy alone LAWRENCEVILLE, N.J.

OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene- M ediated Immunotherapy is Safe and Demonstrates an Acceptable   R isk/ B enefit W hen Administered O ver a Six-Month   Period   with   Up to 17 D oses LAWRENCEVILLE, N.J.

VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , July 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage

LAWRENCEVILLE, N.J. , July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , Celsion GmbH , a wholly owned subsidiary of Celsion Corporation , a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox study with ThermoDox ® in

Celsion GmbH   will manage current and future cancer studies with Thermo D ox ® Celsion   continues its strategic   focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J. , June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage company focused on

Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and   Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. , June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN) , a clinical-stage company focused on DNA-based